mavacamten (Camzyos) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Breakthrough Therapy FDA
AACT PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O
  • InChIKey: RLCLASQCAPXVLM-NSHDSACASA-N
  • Mol. Mass: 273.34
  • ALogP: 2.29
  • ChEMBL Molecule:
    mavacamten  
More Chemistry

Pharmacology

Alternative names

myk-461

Organizations (6)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Cardiomyopathy, Hypertrophic

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Cardiomyopathies (Phase 3)

Cardiomyopathy, Hypertrophic (Phase 4)

Healthy Volunteers (Phase 1)

Heart Failure, Diastolic (Phase 2)

Hypertrophy, Left Ventricular (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue